Scott Dunseth Myers has bought stock on 4 days since Mar 2023

Scott Dunseth Myers is the Chairperson of the Board of Directors at Dynavax Technologies Corporation (DVAX), a position he has held since October 2021.( On August 22, 2025, he purchased 3,800 shares of DVAX common stock at $10.82 per share in an open-market transaction, increasing his direct ownership to 35,004 shares.(

Mr. Myers brings nearly three decades of experience in the global pharmaceutical and medical technology sectors. His career highlights include serving as Chief Executive Officer and President of Viridian Therapeutics in 2023, leading AMAG Pharmaceuticals as CEO through its turnaround and sale to Covis Pharmaceuticals in 2020, and heading Rainier Therapeutics as Chairperson and CEO prior to its asset sale to Fusion Pharmaceuticals.( He was also CEO, President, and Director at Cascadian Therapeutics until its acquisition by Seagen in 2018, and has held board roles at companies including Zentalis Pharmaceuticals, Harpoon Therapeutics, and Cartesian Therapeutics.( Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the University of Chicago Booth School of Business.(

Written by Perplexity from public sources.